@article{9e141b50d2e94aae93568a2df2ec3923,
title = "Moving beyond Medications That Act at the μ Receptor in the Treatment of Opioid Use Disorder",
author = "Strain, {Eric C.} and Kampman, {Kyle M.} and Weiss, {Roger D.}",
note = "Funding Information: consulted, done work for, or served on advisory boards to the following organizations: Analgesic Solutions, Caron, Cerevel, Elsevier, Indivior Pharmaceuticals, VitalHub (The Oak Group), Otsuka Pharmaceutical Development and Commercialization, Pinney Associates, and UpToDate. He is currently collaborating with Masimo/Innovative Health Solutions. Dr Weiss has consulted to Indivior, Alkermes, Analgesic Solutions, Janssen Pharmaceuticals, Braeburn Pharmaceuticals, Daiichi Sankyo, US WorldMeds, Cerevel Therapeutics, and Takeda Pharmaceuticals. Dr Kampman has done work for or served on advisory boards to the following organizations: Indivior Pharmaceuticals, World Meds, Alkermes, Braeburn, Elsevier, and UpToDate. Financial support was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, which has received research contracts, grants, or other revenue from the US Food and Drug Administration, multiple pharmaceutical and device companies, and other sources. No other disclosures were reported.",
year = "2021",
month = jul,
doi = "10.1001/jamapsychiatry.2021.0259",
language = "English (US)",
volume = "78",
pages = "701--702",
journal = "JAMA psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",
}